

Table SVI. *MUC22* expression and association with clinicopathologic parameters in lung cancer patients.

Characteristics	No. of cases	<i>MUC22</i> ^{High} n (%)	<i>MUC22</i> ^{Low} n (%)	P-value
Total	993	311 (31.3)	682 (68.7)	
Sex				
Male	593	143 (24.1)	450 (75.9)	2.1×10 ^{-10b}
Female	399	168 (42.1)	231 (57.9)	
Age (years)				
≥60	744	218 (29.3)	526 (70.7)	0.011 ^a
<60	245	93 (38.0)	152 (62.0)	
Pathological type				
LUAD	499	251 (50.3)	248 (49.7)	7×10 ^{-20b}
LUSC	494	60 (12.1)	434 (87.9)	
Clinic stage				
I	510	159 (31.2)	351 (68.8)	0.835
LUAD		131	137	
LUSC		28	214	
II	279	85 (30.5)	194 (69.5)	0.95
LUAD		64	54	
LUSC		21	140	
III	159	50 (31.4)	109 (68.6)	0.455
LUAD		42	39	
LUSC		8	70	
IV	32	12 (37.5)	20 (62.5)	
LUAD		11	14	
LUSC		1	6	

Data were extracted from the Human Protein Atlas (HPA, <https://www.proteinatlas.org>). Patients with *MUC22*^{Low} or *MUC22*^{High} tumors at different stages were classified based on the cutoff value of 0.02 shown in the HPA. ^aP<0.05 and ^bP<0.001 (χ^2 tests). *MUC22*, mucin 22; LUAD, lung adenocarcinoma; LUSC, lung squamous cell carcinoma.